At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Fragile X Syndrome Treatment with MC01CI Study
The purpose of this study is to evaluate the effects of the investigational drug metadoxine extended release (MDX) on attention deficit symptoms. Attention deficit is a common symptom often associated with fragile X syndrome.
In order to participate you must meet the following criteria:
- Be between ages 15 and 55.
- Be available for 84 days (12 weeks), including follow-up examinations.
This is a partial list of inclusion criteria.